Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Novartis, Alnylam team up to develop RNAi drugs for flu; deal later terminated

15 Apr 2014

Executive Summary

Novartis and Alnylam Pharmaceuticals (developing RNA interference (RNAi) drug candidates) have teamed up to create pandemic flu therapeutics.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By